16 MeV/cにおける反陽子・原子核消滅断面積測定の初の試み

学位の種別: 課程博士審査委員会委員 : (主査)東京大学准教授 小沢 恭一郎, 東京大学教授 櫻井 博義, 東京大学教授 宮武 宇也, 東京大学教授 堀 健太朗, 東京大学准教授 矢向 謙太郎University of Tokyo(東京大学

Microwave spectroscopic study of the hyperfine structure of antiprotonic helium-3

In this work we describe the latest results for the measurements of the hyperfine structure of antiprotonic helium-3. Two out of four measurable super-super-hyperfine SSHF transition lines of the (n,L)=(36,34) state of antiprotonic helium-3 were observed. The measured frequencies of the individual transitions are 11.12548(08) GHz and 11.15793(13) GHz, with an increased precision of about 43% and 25% respectively compared to our first measurements with antiprotonic helium-3 [S. Friedreich et al., Phys. Lett. B 700 (2011) 1--6]. They are less than 0.5 MHz higher with respect to the most recent theoretical values, still within their estimated errors. Although the experimental uncertainty for the difference of 0.03245(15) GHz between these frequencies is large as compared to that of theory, its measured value also agrees with theoretical calculations. The rates for collisions between antiprotonic helium and helium atoms have been assessed through comparison with simulations, resulting in an elastic collision rate of gamma_e = 3.41 +- 0.62 MHz and an inelastic collision rate of gamma_i = 0.51 +- 0.07 MHz.Comment: 15 pages, 9 figures. arXiv admin note: substantial text overlap with arXiv:1102.528

Primary omental Gastrointestinal stromal tumor (GIST)

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens

Guidelines for chemotherapy of biliary tract and ampullary carcinomas

Few randomized controlled trials (RCTs) with large numbers of patients have been conducted to date in patients with biliary tract cancer, and standard chemotherapy has not been established yet. In this article we review previous studies and clinical trials regarding chemotherapy for unresectable biliary tract cancer, and we present guidelines for the appropriate use of chemotherapy in patients with biliary tract cancer. According to an RCT comparing chemotherapy and best supportive care for these patients, survival was significantly longer and quality of life was significantly better in the chemotherapy group than in the control group. Thus, chemotherapy for patients with biliary tract cancer seems to be a significant treatment of choice. However, chemotherapy for patients with biliary tract cancer should be indicated for those with unresectable, locally advanced disease or distant metastasis, or for those with recurrence after resection. That is why making the diagnosis of unresectable disease should be done with greatest care. As a rule, pathological diagnosis, including cytology or histopathological diagnosis, is preferable. Chemotherapy is recommended in patients with a good general condition, because in patients with general deterioration, such as those with a performance status of 2 or 3 or those with insufficient biliary decompression, the benefit of chemotherapy is limited. As chemotherapy for unresectable biliary tract cancer, the use of gemcitabine or tegafur/gimeracil/oteracil potassium is recommended. As postoperative adjuvant chemotherapy, no effective adjuvant therapy has been established at the present time. It is recommended that further clinical trials, especially large multi-institutional RCTs (phase III studies) using novel agents such as gemcitabine should be performed as soon as possible in order to establish a standard treatment